All News
NEJM: Early Combo Monoclonal Antibody Therapy in COVID-19
NEJM has published the interim analysis of the REGN-COV2 trial, wherein an antibody cocktail reduced viral loads with less clinical consequences.
Read Article
Combo Anti-Spike Protein Antibody for Mild to Moderate COVID-19
JAMA has published the BLAZE-1 study, showing significant SARS-CoV-2 viral load reduction at day 11 and less COVID-19 progression when combination anti-spike monoclonal antibody therapy (bamlanivimab and etesevimab) was given to mild to moderate, non-hospitalized COVID-19 patients.
Read Article
Low Risk of TB with Secukinumab
JAMA Dermatology has reported on a longitudinal cohort study of 12,319 secukinumab (SEC) treated patients (psoriasis, psoriatic arthritis, or ankylosing spondylitis); no new cases of active tuberculosis (TB) and very few cases of latent tuberculosis infection (LTBI) were f
Read Article
Inequities in Telemedicine During COVID-19
Health equity in the telehealth age has assumed added importance since the COVID-19 pandemic began. The Federal Communications Commission estimates that about 21 million Americans don't have access to the Internet in their homes. Other sources estimate it is closer to 162 million.
Read Article
Travel During COVID-19 Pandemic
The CDC has addressed the effects and the issues of domestic and international travel on its website. Below is a sampling of key advice.
Read Article
2020 Rheumatology Year in Review
2020 was historic, memorable and game-changing. Under the cloud of COVID-19, there were many significant and memorable advances and setbacks for the rheumatology world. In our accounting of most read articles for 2020, (not surprisingly) 17/20 were COVID-related.
Read Article
RheumNow Podcast – Lights, Camera, Zoom (1.8.2021)
Dr. Jack Cush reviews the news, journal articles and favorite blogs from this past week on RheumNow.com.
Read Article
COVID-19 Vaccination - Phase Ib Begins
The U.S. Centers for Disease Control and Prevention (CDC) has issued a timeline guidance document on when, how and who should get the commercially available COVID-19 vaccines.
Read Article
Plaquenil Does Not Protect Lupus Patients from COVID-19 (Best of 2020)
Annals of Rheumatic Disease reports on an analysis of lupus (SLE) patients that shows COVID-19 infection rates were similar between those lupus patients who were taking hydroxychloroquine (HCQ) and those not taking HCQ.
Read Article
Best of 2020: The COVID-19 Global Rheumatology Registry
What started out as online tweets and sharing newsfeed and case reports, has progressed to the formation of the COVID-19 Global Rheumatology Alliance, whose mission is to create an international rheumatology registry of patients affected by the disease in order to better understand the disease and guide clinicians in assessing and treating patients.
Read Article
Best of 2020: Rheumatic Disease Drugs and COVID-19
We are in the early stages of trying to limit the morbid and mortal consequences of the corona virus pandemic of 2020. Not surprisingly, the recommendations designed to limit exposure and damage continually highlight the fact that the elderly and immunosuppressed may be amongst the most severely affected should they become infected with this virus.
This has led to a great deal of uncertainty by patients and providers about how rheumatic diseases and their treatments need to be specifically addressed.
Best of 2020: The Nine Lives of Hydroxychloroquine (Updated)
Hydroxychloroquine is one of many medications frequently used in rheumatology practice. Its remarkable versatility is attested by its routine use in lupus, in patients with an autoimmune coagulopathy, in patients with rheumatoid arthritis, as well as in those with a low-level inflammatory arthropathy.
Read Article
ACIP Recommendations for Pfizer-BioNTech COVID-19 Vaccine Use (including Special Populations)
Following the FDA issuance of an Emergency Use Authorization for the Pfizer-BioNTech COVID-19 vaccine, the Advisory Committee on Immunization Practices (ACIP) issued interim recommendations for the prevention of COVID-19 in persons aged ≥16 years.
Read Article
COVID-19 as a Leading Cause of Death in the USA
The exponential rise in deaths from the coronavirus (COVID-19) in the last several months is put into perspective by JAMA Viewpoint article noting that current US death rates of > 3000 per day from COVID-19 is greater than that seen in one day on September 11, 2001 (9/11 attacks, claimed 2988 lives) or by a fictional catastrophe of 15 Airbus 320 jetliners (150 passengers each) crashing daily.
Read Article
RheumNow Podcast – Stop These COVID Mistakes (12.11.20)
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.
Read Article
New Lyme Disease Guidelines
2020 evidence-based clinical practice guideline for the prevention, diagnosis, and treatment of Lyme disease was cooperatively developed the Infectious Diseases Society of America (IDSA), the American Academy of Neurology (AAN), and the American College of Rheumatology (ACR).
Read Article
Rheumatic Disease and COVID-19: Who Is at Risk?
Patients with rheumatic and inflammatory diseases who develop COVID-19 share risk factors for severe disease with the larger population, including older age, male sex, obesity, and hypertension, but also are at increased risk if they are on corticosteroids, French investigators reported.
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
